4 Marzo 2019

EU Panel Backs Lorlatinib for ALK+ NSCLC

March 1, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of lorlatinib for the treatment of adult patients with ALK-positive advanced non–small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK TKI, or crizotinib and at least one other ALK TKI. The CHMP recommendation is based on a nonrandomized, dose-ranging, multicohort … (leggi tutto)